Quantification of the Mutant CALR Allelic Burden by Digital PCR: Application to Minimal Residual Disease Evaluation after Bone Marrow Transplantation.
暂无分享,去创建一个
M. Robin | C. James | E. Lippert | F. Mahon | G. Socié | A. Bidet | B. Cassinat | O. Mansier | E. Verger | Marina Migeon | A. Saint-Lézer | Olivier Mansier
[1] J. Chi,et al. Calreticulin mutations in myeloproliferative neoplasms and new methodology for their detection and monitoring , 2015, Annals of Hematology.
[2] E. Solary,et al. Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution , 2014, Leukemia.
[3] S. Langabeer,et al. Assessment of CALR mutations in myelofibrosis patients, post‐allogeneic stem cell transplantation , 2014, British journal of haematology.
[4] J. Kiladjian,et al. Interferon alfa therapy in CALR-mutated essential thrombocythemia. , 2014, The New England journal of medicine.
[5] A. Tordai,et al. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations , 2014, Haematologica.
[6] Min Yu,et al. Detection and quantification of BCR-ABL1 fusion transcripts by droplet digital PCR. , 2014, The Journal of molecular diagnostics : JMD.
[7] J. D. Fitzpatrick,et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.
[8] G. Superti-Furga,et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. , 2013, The New England journal of medicine.
[9] Christopher M. Hindson,et al. Absolute quantification by droplet digital PCR versus analog real-time PCR , 2013, Nature Methods.
[10] T. Barbui,et al. Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study , 2013, Leukemia.
[11] D. Niederwieser,et al. JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse , 2013, Haematologica.
[12] Benjamin J. Hindson,et al. Evaluation of a Droplet Digital Polymerase Chain Reaction Format for DNA Copy Number Quantification , 2011, Analytical chemistry.
[13] T. Barbui,et al. Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. , 2009, Blood.
[14] Y. Hildebrandt,et al. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. , 2009, Blood.
[15] S. Ellard,et al. Concordance of assays designed for the quantification of JAK2V617F: a multicenter study , 2009, Haematologica.
[16] S. Chevret,et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. , 2008, Blood.
[17] R. Mesa,et al. Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival , 2008, Leukemia.
[18] Paola Guglielmelli,et al. Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia. , 2007, Blood.
[19] N. Kröger,et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. , 2007, Blood.
[20] M. Stratton,et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. , 2007, The New England journal of medicine.
[21] P. Campbell,et al. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia. , 2006, Blood.
[22] François Girodon,et al. The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. , 2006, Blood.
[23] Sandra A. Moore,et al. MPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia , 2006, PLoS medicine.
[24] Stefan N Constantinescu,et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. , 2005, Nature.
[25] K. Kinzler,et al. Digital PCR. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[26] Helen E White,et al. Evaluation of methods to detect CALR mutations in myeloproliferative neoplasms. , 2015, Leukemia research.